New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
05:56 EDTCBLICleveland BioLabs downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Cleveland BioLabs calling BARDA's decision to terminate negotiations for the continued development of Entolimod a significant setback.
News For CBLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2015
08:14 EDTCBLICleveland BioLabs awarded new U.S. patents
Cleveland BioLabs announced the allowance or issuance of several new patents for entolimod in the U.S. and other countries, further bolstering its patent position. Cleveland BioLabs, Inc. recently secured an additional composition of matter patent in the U.S. in the patent family that covers the Company's lead agent, the flagellin-derived entolimod, as well as various other flagellin-derived agents, for any use, including the biodefense and medical indications that CBLI is pursuing. Cleveland BioLabs now has more than 10 issued or allowed U.S. patents covering compositions of matter and methods of use claims relating to entolimod's biodefense indication, as well as chemo- and radiation therapy adjuvant and reperfusion injury indications. Additional pending U.S. patent claims include those covering oncology and other biodefense methods of use.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use